CORD-19:3f9572ae671d876279b4d2cd6b6544b24fb3e52d / 30455-30664 JSONTXT

{"project":"CORD-19-Sentences","denotations":[{"id":"TextSentencer_T170","span":{"begin":0,"end":209},"obj":"Sentence"},{"id":"TextSentencer_T170","span":{"begin":0,"end":209},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"150 The latter has been shown to antagonize TGF-β binding to the cell surface receptors of normal and cancer cells by interacting physically with the TGF-β type II receptor and abrogating the binding of TGF-β."}

{"project":"CORD-19-PD-HP","denotations":[{"id":"T76","span":{"begin":102,"end":108},"obj":"Phenotype"}],"attributes":[{"id":"A76","pred":"hp_id","subj":"T76","obj":"http://purl.obolibrary.org/obo/HP_0002664"}],"text":"150 The latter has been shown to antagonize TGF-β binding to the cell surface receptors of normal and cancer cells by interacting physically with the TGF-β type II receptor and abrogating the binding of TGF-β."}

{"project":"CORD-19-PD-MONDO","denotations":[{"id":"T134","span":{"begin":102,"end":108},"obj":"Disease"},{"id":"T84626","span":{"begin":102,"end":108},"obj":"Disease"}],"attributes":[{"id":"A134","pred":"mondo_id","subj":"T134","obj":"http://purl.obolibrary.org/obo/MONDO_0004992"},{"id":"A82966","pred":"mondo_id","subj":"T84626","obj":"http://purl.obolibrary.org/obo/MONDO_0004992"}],"text":"150 The latter has been shown to antagonize TGF-β binding to the cell surface receptors of normal and cancer cells by interacting physically with the TGF-β type II receptor and abrogating the binding of TGF-β."}